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ABSTRACT
Objective Osteoarthritis is a global clinical challenge for 
which no effective disease-modifying agents currently 
exist. This study identifi ed protease-activated receptor 2 
(PAR-2) as a novel pathogenic mechanism and potential 
therapeutic target in osteoarthritis.
Methods Experimental osteoarthritis was induced in 
wild-type and PAR-2-defi cient mice by sectioning the 
medial meniscotibial ligament (MMTL), leading to the 
development of a mild arthropathy. Cartilage degradation 
and increased subchondral bone formation were 
assessed as indicators of osteoarthritis pathology.
Results Four weeks following MMTL section, cartilage 
erosion and increased subchondral bone formation was 
evident in wild-type mice but was substantially reduced 
in PAR-2-defi cient mice. Crucially, the therapeutic 
inhibition of PAR-2 in wild-type mice, using either a 
PAR-2 antagonist or a monoclonal antibody targeting 
the protease cleavage site of PAR-2, was also equally 
effective at reducing osteoarthritis progression in vivo. 
PAR-2 was upregulated in chondrocytes of wild-type 
but not sham-operated mice. Wild-type mice showed 
further joint degradation 8 weeks after the induction 
of osteoarthritis, but PAR-2-defi cient mice were still 
protected.
Conclusions The substantial protection from pathology 
afforded by PAR-2 defi ciency following the induction of 
osteoarthritis provides proof of concept that PAR-2 plays 
a key role in osteoarthritis and suggests this receptor as a 
potential therapeutic target.
Osteoarthritis is a chronic disabling condition cur-
rently affecting millions globally,1 with radiological 
evidence of osteoarthritis in approximately 80% of 
the population aged over 65 years.2 Osteoarthritis 
is characterised by cartilage degradation and 
increased subchondral bone formation (osteo-
sclerosis). Despite extensive pathophysiological 
investigations, clinical management has not altered 
signiﬁ cantly and comprises the administration of 
analgesics and non-steroidal anti-inﬂ ammatory 
agents and recourse upon joint failure to arthro-
plasty. No unifying pathogenetic model exists—
suggested hypotheses encompass primary cartilage 
metabolic dysregulation, enthesial disease together 
with biomechanical dysregulation. Thus far, no crit-
ical checkpoint pathway has been identiﬁ ed that is 
essential for disease progression and which might 
by corollary represent a valid, disease-modifying 
osteoarthritis therapeutic target. Protease-activated 
receptor 2 (PAR-2) is a G-protein coupled recep-
tor whose ‘tethered’ ligand is activated by serine 
proteases.3 PAR-2 is present in chondrocytes in 
cartilage from osteoarthritis patients,4 and follow-
ing its activation, matrix metalloproteases (MMP) 
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are generated.5 However, these previous observa-
tions are associative and do not establish the role 
of PAR-2 in the pathogenesis of osteoarthritis. In 
this study we sought direct evidence of a causal 
relationship between PAR-2 expression and car-
tilage and bone pathology in a murine model of 
osteoarthritis.
METHODS
Animals
Experiments were performed on adult wild-type 
(PAR-2+/+) C57BL/6J mice (body weight 25–30 g), 
housed in standard cages, with food and water 
freely available and maintained in a thermoneutral 
environment. PAR-2-deﬁ cient (PAR-2-/-) mice were 
genetically modiﬁ ed6 and maintained under the 
same conditions. All procedures were performed in 
accordance with UK Home Ofﬁ ce regulations.
Induction of experimental osteoarthritis
Two previously described models of joint insta-
bility were employed.7 The principal model used 
involved destabilisation of the medial meniscus 
by section of the medial meniscotibial ligament 
(MMTL), which results in the development of a 
mild arthropathy resembling human osteoarthri-
tis.7 A more severe model, involving anterior cru-
ciate ligament (ACL) transection, was induced in 
a smaller group of mice.7 All surgical procedures 
were performed by the same investigator who was 
blinded to genotype or treatment. Following sur-
gery, animals were left for 4 or 8 weeks and there-
after, knee joints were harvested for subsequent 
histological analysis. Knee joint diameter was mea-
sured weekly for a month following MMTL surgery 
in a small cohort of mice, but no signiﬁ cant differ-
ence occurred over time (p=0.6, one-way analysis 
of variance (ANOVA), n=6). As similar results were 
obtained with the ACL section model, no further 
such measurements were performed.
Assessment of cartilage damage
Histological analysis of progression and severity 
of cartilage damage was undertaken on harvested 
joints, involving decalciﬁ cation by incubating knee 
joints in 4% paraformaldehyde solution followed 
by phosphate buffer and then in 10% EDTA solu-
tion at 4°C for 2 weeks. Joints were embedded in 
parafﬁ n wax and frontal sections (6 μm) cut at 200 
μm intervals, followed by staining with haema-
toxylin, safranin-O/fast green. Ten sections from 
each mouse were graded using a validated scoring 
system,7 from 0 (normal) to 6 (>80% loss of carti-
lage) by two scorers blinded to the specimens, tak-
ing each quadrant of the joint separately and then 
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summing scores. There was close agreement between scorers 
(intraclass correlation coefﬁ cient 0.97; 95% CI 0.95 to 0.98) 
with the mean difference in score being −0.05 (95% CI 0.01 to 
−0.11).
Assessment of osteosclerosis
From the sections obtained above, two were chosen at random, 
digitally captured (Olympus BX51, DP70, AnalySIS software) and 
stored for computerised planimetry analysis using QS Onscreen 
v 3.1.19, (E-quantities Ltd; http://www.e-quantities.com). Only 
two photomicrographs per mouse were required for planimetric 
analysis as osteosclerosis was relatively consistent across sec-
tions (coefﬁ cient of variation 2.1%). The area of the medial and 
lateral aspects of the tibial plateau was traced, from the epiphys-
ial plate to the lower zone of cartilage adjacent to subchondral 
bone. The tibial plateau region was selected as cartilage damage 
was maximal at the medial aspect with the lateral region never 
appearing to be affected in MMTL-sectioned wild-type mice, 
and so could be used as an internal reference. Controls were also 
performed in sham-operated as well as naive mice. Once the 
overall area on each side of the tibial plateau was determined, 
areas containing marrow were traced, summed and subtracted 
from the overall area on each side to yield the area occupied by 
bone. Comparisons were made by expressing as the percentage 
area occupied by bone in the medial tibial compared with the 
lateral region in order to normalise for animal size, because anal-
ysis of naive mice showed the difference between these areas 
to be minimal (1.1±3.4%, mean±SEM, n=5). Scores were inde-
pendently veriﬁ ed by another blinded assessor and there was 
good agreement between scorers (intraclass correlation coefﬁ -
cient 0.91; 95% CI 0.77 to 0.97) with the mean difference in 
score being 2.7% (95% CI 5.45 to −0.06). Osteosclerosis was 
not assessed in the ACL model as it was previously reported 
that bone erosion can penetrate to the epiphysial plate.7
Immunohistochemistry
Following decalciﬁ cation, sections were deparafﬁ nised, rehy-
drated and stained with the murine monoclonal antibody SAM-
11 (Santa Cruz Biotechnology, Santa Cruz, California, USA) at 
1 μg/ml using the Dako (Ely, UK) animal research kit peroxidase. 
SAM-11 is a highly speciﬁ c monoclonal antibody to human 
PAR-2 that binds the membrane-bound part of the receptor. 
Antigen–antibody complex was visualised utilising diamin-
obenzidine and counterstained with haematoxylin. The animal 
research kit was utilised to minimise the reactivity of secondary 
anti-mouse antibody with endogenous immunoglobulin.
Statistical analysis
Data were tested for normality (Sigmastat 2.03; SPSS Inc) and 
expressed as mean±SEM with comparisons by one or two-way 
ANOVA and multiple comparisons using Bonferroni correc-
tion. Non-normal data were transformed (square root) before 
statistical analysis and if normality was still not achieved, non-
parametric methods were used. Agreement between scorers 
was assessed graphically using the Bland–Altman plot8 and 
expressed as the intraclass correlation coefﬁ cient.
RESULTS
Four weeks after MMTL section, immunohistochemical analy-
sis of cartilage revealed increased PAR-2 expression in superﬁ cial 
layer chondrocytes (ﬁ gure 1A), compared with sham-operated 
mice (ﬁ gure 1B). Having established enhanced expression of the 
PAR-2 pathway with plausible tissue distribution, pathology 
was compared in wild-type mice (PAR-2+/+; n=5) and PAR-2-
deﬁ cient littermates (PAR-2-/-; n=5), with sham-operated wild-
type mice (n=4) serving as a negative control. Compared with 
sham-operated mice (ﬁ gure 1D), PAR-2+/+ mice showed cartilage 
damage and increased subchondral bone formation (ﬁ gure 1E), 
whereas such changes were minimal in PAR-2-/- mice (ﬁ gure 1F). 
Such differences could not be attributed to an underlying differ-
ence in bone phenotype of PAR-2-/- mice as the appearance of 
the unoperated knee did not differ from wild-type littermates 
(supplementary ﬁ gure 1, available online only). To address the 
therapeutic utility of PAR-2, operated mice (n=6) were treated 
with SAM-11 antibody, which we previously demonstrated 
inhibits PAR-2 activation.9 In a further group (n=5), we utilised 
p520, a selective PAR-2 antagonist.10 Consistent with data in the 
PAR-2-deﬁ cient animals, mice treated with SAM-11 (ﬁ gure 1G) 
or p520 showed signiﬁ cantly reduced osteoarthritis pathology 
4 weeks postoperatively (ﬁ gure 1H,I).
Figure 1 Protease-activated receptor 2 (PAR-2) absence or inhibition 
ameliorates osteoarthritis pathology in the 4-week medial meniscotibial 
ligament (MMTL) model. Immunohistochemistry of cartilage in the 
medial tibial aspect using SAM-11 to detect PAR-2 shows increased 
surface expression in chondrocytes of the wild-type mouse following 
MMTL section (A), compared with a sham-operated animal (B), with 
isotype control (C). Bar indicates 50 µm. Histological appearances 
of the medial aspect of the knee joint 4 weeks after sham-operation 
(D), or following MMTL section in either a wild-type (E) or PAR-2-
defi cient mouse (F), or wild-type mouse treated daily with SAM-11 
(1 µg intraperitoneally) immediately before and after the induction 
of osteoarthritis (G). Arrowheads in (E) denote cartilage damage and 
asterisk indicates osteosclerosis. Scale bar in panel F indicates 500 µm 
and applies to all four photomicrographs. Cartilage degradation scores 
(H) for the medial tibial (MT), medial femoral (MF), lateral tibial (LT) and 
lateral femoral (LF) regions following MMTL section in PAR-2+/+ and 
PAR-2-/- mice, PAR-2+/+ mice treated with PAR-2 antagonist p520 (5 mg 
intraperitoneally daily), SAM-11 (1 µg intraperitoneally daily) or isotype 
(IgG2a) control antibody (ISO; 1 µg intraperitoneally daily), along with 
sham-operated controls. Data are expressed as mean±SEM, n=4–6. 
Analysis by one-way analysis of variance (ANOVA) with multiple 
comparisons using the Bonferroni correction, *p<0.05; **p<0.01; 
***p<0.001. †p<0.005, Mann–Whitney rank sum test. Percentage 
difference in bone area (I) comparing the medial and lateral tibial 
regions following MMTL transection in the above groups of mice along 
with a naive control group. Analysis by one-way ANOVA with multiple 
comparisons using the Bonferroni correction, *p<0.05; **p<0.02; 
***p<0.01. §p<0.001, t test. NS, not signifi cant.
A D
F
H I
G
E
B
C
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Two-way ANOVA revealed a signiﬁ cant difference in car-
tilage degradation between groups (p<0.0001) and between 
regions (p<0.0001). PAR-2+/+ mice exhibited signiﬁ cantly 
greater cartilage degradation than sham-operated, PAR-2-/- 
mice, or wild-type mice treated with p520 (ﬁ gure 1H). Similarly, 
operated mice receiving an isotype antibody developed sub-
stantially greater cartilage degradation than SAM-11-treated 
mice. Consistent with previous work,7 cartilage damage only 
occurred at the medial aspects of the tibia and femur. Analysis 
of subchondral bone revealed differences between treatment 
groups (p=0.006, one-way ANOVA). PAR-2+/+ mice differenti-
ated from sham-operated, PAR-2-/- mice, and wild-type recipi-
ents of p520 (ﬁ gure 1I). Consistent with this, mice receiving 
isotype control showed substantially greater osteosclerosis than 
SAM-11 recipients. Cartilage damage and osteosclerosis scores 
were signiﬁ cantly correlated (r=0.7, p<0.0001). As genetic deﬁ -
ciency of PAR-2, or inhibition by two distinct routes, namely 
targeting the protease cleavage site with SAM-11 or directly 
by receptor antagonism, proved effective in preventing the 
development of experimental osteoarthritis, we conclude that 
PAR-2 is a pivotal checkpoint in early progression of osteoar-
thritis pathology.
The longer-term effects of PAR-2 biology were examined using 
PAR-2-deﬁ cient mice by extending the postoperative period 
to 8 weeks. Compared with wild-type littermates  (ﬁ gure 2A) 
cartilage damage was still signiﬁ cantly (p<0.0001, two-way 
ANOVA, n=7–8) lower in PAR-2-/- mice (ﬁ gure 2B,C) and once 
again the latter showed no evidence of increased subchondral 
bone formation, whereas PAR-2+/+ mice showed a signiﬁ cant 
increase compared with the 4-week model (ﬁ gure 2D). To test 
our hypothesis further, the more aggressive ACL transection 
model was investigated. PAR-2+/+ mice developed almost com-
plete cartilage erosion, particularly at the medial femoral con-
dyle (ﬁ gure 3A,C), whereas PAR-2-/- mice exhibited signiﬁ cantly 
(p<0.0001, two-way ANOVA, n=7–8) lower levels of damage 
(ﬁ gure 3B,C).
DISCUSSION
Our observations in PAR-2-deﬁ cient mice using both MMTL 
and ACL transection models provide powerful proof of concept 
for a key role of PAR-2 in joint degradation associated with oste-
oarthritis, and furthermore demonstrate the therapeutic poten-
tial of PAR-2 inhibition, which could have preventive clinical 
utility. The mechanism by which PAR-2 promotes osteoarthritis 
has yet to be clariﬁ ed. PAR-2 provides for sensing by cells of 
the protease environment and allows them to respond subse-
quently. For example, PAR-2 regulates the synovial release of 
proinﬂ ammatory cytokines including interleukin-1β,11 which is 
in turn a potent chondrocyte catabolin.12 Activation of PAR-2 
leads to the inhibition of osteoclast differentiation13 and could 
alter the balance between bone formation and resorption, and 
thereby contribute to osteosclerosis observed in PAR-2+/+ but 
not PAR-2-/- mice. However, whether PAR-2 has a direct or indi-
rect effect on the bone phenotype and its hierarchical role in 
osteoarthritis are areas for further investigation. Earlier studies 
revealed that selective PAR-2 activation of chondrocytes derived 
from human osteoarthritis cartilage leads to the generation of 
MMP-1 and MMP-13,5 both of which are known to play a key 
role in the degradation of aggrecan and collagens. Although 
the initiating event in the development of osteoarthritis lesions 
remains unknown, our data suggest that PAR-2 is a crucial 
checkpoint that mediates the effect of biomechanical instability 
upon cartilage degradation and osteosclerosis. PAR-2 inhibitors 
could therefore provide a new direction in the development of 
disease-modifying osteoarthritis drugs, which following disap-
pointing results of trials with MMP inhibitors, biphosphonates 
and cytokine inhibition,14 still remain elusive.
Figure 2 Protease-activated receptor 2 (PAR-2) defi ciency still 
confers protection 8 weeks after medial meniscotibial ligament (MMTL) 
section. Examination of the medial tibial and femoral regions of the 
PAR-2+/+mouse (A) compared with its PAR-2-/- littermate (B) 8 weeks 
after MMTL section shows continued protection in the latter. Scale bars 
indicate 500 µm. This was confi rmed for these two groups (n=7 and 
8, respectively) in terms of cartilage damage scores (C). **p<0.01, 
***p<0.001. Osteosclerosis, comparing the percentage difference 
in bone area between the medial and lateral tibial areas, showed a 
signifi cant increase in the 8-week model (MMTL8) compared with 
4 weeks (MMTL4) in PAR-2+/+ mice but no difference between the 
PAR-2-/- groups (D). *p<0.02, **p<0.0001. LF, lateral femoral; LT, 
lateral tibial; MF, medial femoral; MT, medial tibial.
A C
DB
Figure 3 Eight weeks after anterior cruciate ligament transection, 
substantial damage was evident in multiple areas of the knee in 
protease-activated receptor 2 positive (PAR-2+/+) mice (A), but less 
so in PAR-2-defi cient (PAR-2-/-) mice (B). Scale bar indicates 1000 µm. 
Cartilage damage scores confi rm the more extensive nature of damage 
in this model of arthritis, but there remain signifi cant differences 
compared with PAR-2-/- mice (C). ***p<0.001, **p<0.005, *p<0.05. 
LF, lateral femoral; LT, lateral tibial; MF, medial femoral; MT, medial tibial.
A
B
C
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